MENLO PARK, Calif.,
Sept. 12, 2018 /PRNewswire/ --
BioPharmX Corporation (NYSE American: BPMX), a specialty
pharmaceutical company developing products for the dermatology
market, today announced the appointment of David S. Tierney, M.D., as its chief executive
officer. Anja Krammer continues to serve in her roles as
president and corporate secretary for BioPharmX. Dr. Tierney was
also appointed as a director to the board of directors of
BioPharmX. BioPharmX Corporation noted that Dr. Tierney is an
accomplished healthcare executive with a proven record of
achievements leading the growth of both pharmaceutical and medical
device companies. Additionally, Dr. Tierney possesses significant
experience in successfully developing and commercializing drug
delivery platforms, which will be a particularly valuable asset for
BioPharmX as it commercializes its own topical dermatology
technology.
"We look forward to having a seasoned industry veteran such as
David join our team as we advance our topical dermatology clinical
programs and commercialization strategies," said Michael L. Hubbard, chairman of the board of
directors of BioPharmX Corporation. "David brings a wealth of
expertise in medical science, clinical, and regulatory affairs, and
in overseeing the advancement of healthcare companies from the
product development phase to commercial operations."
David Tierney commented,
"BioPharmX is on the threshold of an important and exciting growth
phase as is evident from the company's robust product pipeline and
its lead product candidate being phase 3-ready for acne." He
further noted, "I expect advancements in BioPharmX product
development to drive increased corporate visibility and
transformational changes in dermatologic pharmaceuticals. I am
thrilled to have the opportunity to participate and contribute to
BioPharmX's growth prospects."
About David S. Tierney,
M.D.
Prior to his appointment as CEO at BioPharmX, he was
president and CEO of Icon Bioscience where he led a team that in
2018 received U.S. FDA approval of its New Drug Application (NDA)
for DEXYCU™ (dexamethasone intraocular suspension), a dropless,
long-acting therapeutic for treating inflammation associated with
cataract surgery. Icon was merged with EyePoint Pharmaceutical in
March 2018.
Dr. Tierney served as president and chief operating officer of
Oceana Therapeutics, Inc., a specialty therapeutic company he
co-founded in 2008. Oceana quickly established a global commercial
network and by 2011 was acquired by Salix Pharmaceuticals. In 2000,
David was appointed President & CEO of Hydro Med Sciences
(HMS), a research firm with a promising drug delivery platform.
Under his leadership, HMS emerged as Valera Pharmaceuticals, a
fully integrated, commercial, specialty pharma company that
successfully completed an initial public offering in 2005. Valera
has since been merged into Endo Pharmaceuticals. Prior to Valera,
Dr. Tierney was president of Biovail Technologies, a drug delivery
division of Biovail Corporation - a predecessor to Valeant
Pharmaceuticals International. Earlier in his career, he served as
senior vice president of drug development at Roberts Pharmaceutical
and in a variety of management positions at Elan Corporation. Dr.
Tierney received his medical degree from Royal
College of Surgeons in Ireland.
David Tierney is the recipient of
two Ernst & Young Entrepreneur of the
Year® awards, first in 2005 and again in
2011, respectively, reflecting his accomplishments at Valera and
Oceana. He was also featured in the inaugural 2010 Irish
Life Science 50, an honor presented by the president
of Ireland in conjunction
the Irish
Voice and Irish America
Magazine. Additionally, in 2005, 2006, and 2011,
PharmaVOICE 100 named David one of the most inspiring
people in health sciences.
About BioPharmX Corporation
BioPharmX
Corporation (NYSE American: BPMX) is a Silicon Valley-based
specialty pharmaceutical company, which seeks to provide products
through proprietary platform technologies for prescription,
over-the-counter (OTC), and supplement applications in the health
and wellness markets, including dermatology and women's health. To
learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
This press release contains forward-looking statements related to
the company's plans, developments or growth prospects that involve
risks, uncertainties and assumptions, and are subject to the "safe
harbor" of the Private Securities Litigation Reform Act of 1995.
These statements may be identified by words such as "plan,"
"expect," "believe," "intend," "should," "may" or similar
expressions. Important factors that could cause actual results to
differ materially than those expressed or implied in such
statements include, but are not limited to, the company's ability
to complete clinical studies and advance its product candidates
through regulatory approval, to commercialize its drug delivery
program and to obtain patent protection and defend its intellectual
property and to raise capital. Additional risks are set forth in
the company's filings with the Securities and Exchange Commission,
including those described in the company's Quarterly Report on Form
10-Q for the most recent fiscal quarter. The forward-looking
statements included in this news release are made only as of the
date hereof, and the company undertakes no obligation to publicly
update such statements.
BioPharmX is a registered trademark of BioPharmX, Inc.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biopharmx-corporation-announces-david-s-tierney-md-joined-the-company-as-chief-executive-officer-300711668.html
SOURCE BioPharmX Corporation